Early ARTs were developed based on the observed low count of CD4+ T-Cells in clinical symptoms of AIDS as compared to the most recent ones that are administered immediately after a patient is diagnosed regardless of the level of CD4+ cells [7]. The gene discussed is CD4; the disease is AIDS.